Evidence map›Paper›PMID 36253555›Full record

ReviewNature reviews. Immunology2023

Allergen immunotherapy: past, present and future.

Stephen R Durham, Mohamed H Shamji

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06876506 (Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy), which is not on this map. Cited by 201 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 6 pooled it
46.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06876506 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy

TypeobservationalSponsorHull University Teaching Hospitals NHS TrustRan2026 to 2027Enrolled80ConditionsPollen Allergy, Venom AllergyArmsVenepuncture, Allergen Specific Immunotherapy
3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 6 syntheses or guidelines pooled it, 352 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024
    Guideline
  7. Trial
  8. Trial
  9. Comparative safety analysis of coseasonal versus preseasonal Artemisia annua sublingual immunotherapy for allergic rhinitis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Dynamic regulation of CD300b and CD300f on myeloid cells in oral immunotherapy.The journal of allergy and clinical immunology. Global · 2026
    Article
  14. Review
  15. Recent advances in allergen immunotherapy.Chinese medical journal · 2026
    Review
  16. Article
  17. Article
  18. Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  19. Review
  20. Article

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Stephen R DurhamAllergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK. s.durham@imperial.ac.uk.ORCID 0000-0001-5264-6207
Mohamed H ShamjiAllergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK. m.shamji99@imperial.ac.uk.
Lung Institute · US

Funding

Medical Research Council
6 · The paper itself

Abstract

Allergen immunotherapy is a form of therapeutic vaccination for established IgE-mediated hypersensitivity to common allergen sources such as pollens, house dust mites and the venom of stinging insects. The classical protocol, introduced in 1911, involves repeated subcutaneous injection of increasing amounts of allergen extract, followed by maintenance injections over a period of 3 years, achieving a form of allergen-specific tolerance that provides clinical benefit for years after its discontinuation. More recently, administration through the sublingual route has emerged as an effective, safe alternative. Oral immunotherapy for peanut allergy induces effective 'desensitization' but not long-term tolerance. Research and clinical trials over the past few decades have elucidated the mechanisms underlying immunotherapy-induced tolerance, involving a reduction of allergen-specific T helper 2 (T

Indexed as

HypersensitivityAdministration, SublingualAllergensB-LymphocytesDesensitization, ImmunologicHumansAllergens

Identifiers

PMID36253555
PMCPMC9575636
OpenAlexW4306411699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.